The Rationale Behind the Announcement
On April 13, 2026, Stryker Corporation signed a definitive agreement to acquire Amplitude Vascular Systems (AVS), a private company founded in Boston in 2017 that is developing a next-generation intravascular lithotripsy system—known as Pulse IVL—to treat calcified peripheral arterial disease. Financial terms were not disclosed. The technology remains investigational: it received an investigational device exemption from the FDA in June 2024 and is not yet commercially authorized.
Viewed in isolation, the announcement seems like a tactical move. However, in light of Stryker's recent history, it reveals something more structural: the company is actively reshaping its portfolio toward the cardiovascular segment, reallocating capital from its established bases in orthopedics, endoscopy, and robotics into a market where it does not yet dominate. Fourteen months prior, in February 2025, Stryker completed the acquisition of Inari Medical for $4.9 billion, specializing in thrombectomy devices. AVS is the next link in that chain.
What I find worth analyzing is not the technology itself—the clinical validation for intravascular lithotripsy as a method to fracture calcium deposits in arteries without open surgery is already established—but the decision-making architecture behind this sequence of acquisitions. Stryker generates $25.12 billion in annual revenue and has a market capitalization exceeding $130 billion. At that scale, every acquisition carries a massive opportunity cost. The relevant question is whether the company knows how to manage assets at radically different stages of maturity within the same portfolio.
Why Intravascular Lithotripsy Became a Corporate Battleground
Consolidation around intravascular lithotripsy did not start with Stryker. Johnson & Johnson set the pace in 2024 by acquiring Shockwave Medical for $13.1 billion, establishing itself as the undisputed leader in the segment. Boston Scientific entered in January 2025 by acquiring the remaining stake in Bolt Medical for $664 million, with its system gaining FDA authorization in April of that year. Abbott received its own investigational exemption for coronary use in March 2025.
The pattern is clear: large medical corporations recognized that intravascular lithotripsy would shift from a niche technique to a high-volume procedure for complex calcified lesions, and they decided to buy rather than develop. Stryker may be late to the category, but it bets on technological differentiation, not first mover advantage. Analyst Mike Kratky of Leerink Partners described AVS's Pulse system as one of the most credible next-generation competitors to Shockwave's leadership. That characterization matters: it is not a me-too technology, but a platform leveraging pressure waves generated by pulsed CO₂ to offer greater treatment speed and better catheter delivery in peripheral and coronary lesions.
The operational dilemma this poses for Stryker is more complex than it appears in the press release. AVS is a company in pivotal trial phase. It does not yet have a marketable product. Integrating that asset into the machinery of a corporation with a price-to-earnings ratio of 40 times and quarterly pressures on its mature divisions creates a tension that early-stage acquisitions often underestimate.
The Risk of Measuring Immaturity with Established Metrics
This is where most large corporations make the costliest portfolio mistake: they absorb an exploratory-stage company and apply the same management criteria they use for their consolidated business units. The predictable outcome is that the acquired asset loses the execution speed that made it valuable while the acquiring company assumes that integration is progressing because reports are being filled out.
Stryker has evidence in its favor: its acquisition history in the vascular segment suggests it understands these assets need time before generating returns. CEO Kevin Lobo described the agreement as a step toward building a comprehensive peripheral vascular platform, not as an immediate revenue generator. This is a sign that there is, at least in rhetoric, an awareness of the time horizon.
But rhetoric is not the mechanism. What determines whether an acquisition like this works is the governance structure established for AVS within Stryker post-close. If the Pulse IVL team operates with real autonomy, using clinical and regulatory learning metrics rather than sales profitability metrics, the asset has a chance to mature. Conversely, if it becomes subordinate to the reporting dynamics of the peripheral vascular devices division—where mature products already exert pressure on margins—the pace of development will slow in ways that no external communication will make visible.
AVS entered into this agreement already having received its investigational exemption from the FDA, with promising preliminary clinical data shared by late 2025, and backing from investors such as BioStar Capital and Cue Growth Partners. That nine-year trajectory from its founding in 2017 to a definitive agreement with a $130 billion company reflects a development discipline that deserves to be preserved, not diluted within multilayered corporate approval structures.
The transaction's closure is subject to usual regulatory conditions. Until then, both companies operate independently. What occurs in the first 18 months post-close—decisions about reporting structure, autonomy of the founding team, regulatory progress indicators, and resource allocation for the pivotal trial—will determine whether Stryker paid for an asset or for a capability.
The Portfolio Bet Stryker is Building
Viewed through a portfolio lens, Stryker is executing a deliberate transition: its historical revenue engine—orthopedics, surgical robotics, hospital equipment—continues to generate the cash that finances vascular exploration. Inari Medical contributes capabilities in venous thrombectomy, a high-growth market. AVS adds the dimension of calcium modification in peripheral arterial disease. The combination of both, once Pulse IVL receives commercial authorization, would position Stryker with a peripheral vascular offering that spans from thrombus obstruction to severe calcification.
This architecture makes strategic sense. The risk lies not in the direction but in the speed of regulatory execution and in the organization’s ability to sustain the development of an investigational asset without subjecting it to short-term pressures that do not match its stage of maturity. Stryker's $25.12 billion in annual revenue provides the financial cushion to absorb the cost of that wait. What cannot be bought is the organizational discipline to protect the space where that wait occurs.
Stryker has the resources to make this bet work. The variable that the market cannot audit from the outside is whether the internal governance post-acquisition is designed to maximize the probability that Pulse IVL reaches the market with the same speed and clinical focus that brought it this far.
